Imaging serotonin changes before Parkinson's disease in SNCA gene carriers
Uses PET scans to study serotonin system changes in adults with SNCA gene mutations.
Key facts
- Who runs it
- Institut National De La Sante Et De La Recherche Medicale
- Where
- BRON cedex and PARIS, FranceSee the 2 sites
- Trial code
- Registry title
- Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 50 people, planned
- Started
- 1 Sept 2025
- Expected to end
- 1 Mar 2029
- Type of study
- Interventional
- Record updated
- 10 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 in several groups: people with Parkinson's disease, close relatives of people with an SNCA gene mutation, and healthy controls. It studies the serotonin system with brain scans.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Parkinson's disease diagnosed by the 2015 Movement Disorder Society criteria (slowness of movement plus stiffness or resting tremor), or no Parkinson's symptoms for relatives and healthy controls.
- Earlier treatment
- People taking neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine or amphetamine-type drugs must be willing and medically able to stop them for at least 5 half-lives before the DaTSCAN scan.
- Biomarker or test result
- Some patients have an SNCA gene mutation (point mutation or duplication/triplication), some do not. Relatives must be a parent, sibling or child of a patient with an SNCA mutation.
Main reasons for not taking part
- Cannot have an MRI or PET scan (for example claustrophobia, certain implants)
- Another significant brain or nerve disease besides Parkinson's disease
- Antidepressants or other drugs acting on serotonin in the last 3 months
- Pregnant or breastfeeding, or women who could become pregnant without highly effective contraception
- Joined another drug trial in the last 30 days
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Males and females with an age range of 18–80 years at the time of signing the informed consent
- Participant affiliated with or beneficiary of a French social security system or of such a regime
- Diagnosis of PD according to the 2015 Movement Disorder Society criteria, with bradykinesia AND at least ONE of the following: muscular rigidity, or resting tremor; with no other suspected cause of Parkinsonism for Symptomatic PD patients with and without SNCA mutation
- With documented point mutation or multiplication (i.e., duplication/triplication) mutation on the α-synuclein gene (SNCA) for Symptomatic PD patients with and without SNCA mutation
- Or without documented mutation in the SNCA gene for Symptomatic PD patients with and without SNCA mutation
- First degree relative of a PD patient with a known point mutation or multiplication in the SNCA gene (parent, sibling, or child) for Relatives of SNCA gene mutation carriers, without a diagnosis of PD
- Asymptomatic for PD symptoms, and not meeting Diagnosis of PD according to the 2015 Movement Disorder Society criteria for Healthy controls and Relatives of SNCA gene mutation carriers, without a diagnosis of PD
- Able to perform the assessments planned for the study (including brain imaging) according to investigator opinion
- Informed consent obtained from the patient or/ and a legal representative when appropriate
- For subjects taking any of the following drugs (Neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative) must be willing and medically able to hold the medication for at least 5 half-lives before DaTSCAN imaging
Who cannot take part
- Participation in investigational drug trials within 30 days prior to screening or within 5 half-life of investigational product whatever the longest
- Subjects treated with specific serotonin reuptake inhibitors, noradrenalin or serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase type A inhibitors, neuroleptics impacting the serotoninergic system or recreative drugs impacting the serotonergic system in the last 3 months
- Contraindication to MRI such as claustrophobia, epilepsy, severe movement disorders or inability to lay flat that, in the investigator's judgment, precludes the subject's safe participation in and completion of the study. Subjects with a history of working with metal (using grinders, etc.) should have a safety check for residual metal fragments in their eyes to avoid damage from the magnetic fields
- Active disease which could interfere with study conduct as per investigator’s judgement
- For participants undergoing optional skin sampling: any contraindication to this procedure including : - Anticoagulant or antiplatelet therapy, - History of hemostasis disorders, - Bleeding risk verified by a coagulation test
- Presence or known medical history of clinically significant neurological disorder other than PD
- Implanted devices such as stimulators, spinal rods, aneurysm clips, cardiac pacemaker, hearing device, metallic contraceptive device, insulin pump, artificial implants, peripheral or neuronal stimulator, intravenous catheter that would interfere with MRI interpretation
- Known Hypersensitivity to ioflupane or to any excipients of DaTSCAN®
- For participants undergoing optional lumbar puncture (LP): Any contraindication to LP procedures, including but not limited to: a. Known or suspected structural abnormality of the lumbar spine, including but not limited to X-ray, MRI, or myelographic evidence of significant lumbar spine abnormalities, or other anatomical factors at or near the LP site that, in the opinion of the Investigator, may interfere with the performance of the LP, render repeated LPs difficult, or increase the risk of the procedure for the participant. b. Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and might place a participant at an increased risk for intraoperative or postoperative bleeding. These could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities), known underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, von Willebrand’s disease, liver disease), clinically significant abnormal lab values increasing the risk of bleeding regarding platelets count, INR or PT or aPTT. - Low platelet count (below 50,000 cells/μL)(Hemostasis test must be done 72h max prior to the LP. A medical prescription will be sent to the participant to check whether his/her coagulation level is in accordance with this intervention.), - Screening values of International Normalized Ratio (INR), Prothrombin time (PT), or Activated Partial Thromboplastin Time (APTT) that are not within normal ranges (determined by the laboratory performing the analyses), - Taking any antiplatelet medication (e.g., aspirin >81 mg daily, clopidogrel, or nonsteroidal anti-inflammatory drugs [NSAIDs]) within 7 days prior to the planned LP or anticipated need for antiplatelet medication within 48 hours after an LP, - Taking anticoagulant medication (warfarin, heparinoids, and direct coagulation factor inhibitors, e.g., apixaban, dabigatran, rivaroxaban) c. Presence of intracranial hypertension d. Puncture site infections e. Patients treated with Deep Brain Stimulation
- Pregnant and lactating women; Women of childbearing potential (WOCBP) tested positive in serum or urine pregnancy test (The following may be considered as highly effective contraception: progestogen-only or combined (estrogen and progestogen containing) hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner (if the 22/58 SerIAL-PD_Protocol_V1.0_18032025 partner is the sole sexual partner of the WOCBP participant for the duration of the study) or abstinence (depending on the participant's lifestyle))
- Any factor which might create an unjustified risk for the participant
- Minors or subjects benefiting from laws aimed at protecting vulnerable adults: subjects being deprived of liberty by judicial or administrative decision, subjects under guardianship /curatorship
- Participant within the exclusion period in the National Register for participants of the French Ministry of Health
- Contraindication to PET imaging or DaTSCAN®
- Significant brain abnormalities that could interfere with accurate brain imaging analysis
- Impaired comprehension interfering with an informed consent in the opinion of the investigator
- WOCBP without a highly effective contraception
Where in France
- CERMEP - imagerie du vivantBRON cedex, FranceNot yet recruiting
- APHP - Hôpital Universitaire Pitié-SalpêtrièrePARIS, FranceNot yet recruiting
About the trial
What the trial wants to find out
To investigate the early alteration of the serotoninergic system at the prodromal stage of Parkinson’s disease (PD) using the radiotracers [11C]DASB and [11C]SB207145 in participants with alpha-synuclein SNCA gene mutations (SNCA+ PD-), compared with healthy controls (SNCA- PD-).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET using [11C]DASB and [11C]SB207145 : SerIAL-PD
- Plain-language title
- Imaging serotonin changes before Parkinson's disease in SNCA gene carriersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 10 February 2026